-
Mashup Score: 7Spatially Segregated Macrophage Populations Predict Distinct Outcomes In Colon Cancer - 1 month(s) ago
Abstract. Tumor-associated macrophages are transcriptionally heterogeneous, but the spatial distribution and cell interactions that shape macrophage tissue roles remain poorly characterized. Here, we spatially resolve five distinct human macrophage populations in normal and malignant human breast and colon tissue and reveal their cellular associations. This spatial map reveals that distinct macrophage populations reside in spatially segregated micro-environmental niches with conserved cellular compositions that are repeated across healthy and diseased tissue. We show that IL4I1+ macrophages phagocytose dying cells in areas with high cell turnover and predict good outcome in colon cancer. In contrast, SPP1+ macrophages are enriched in hypoxic and necrotic tumor regions and portend worse outcome in colon cancer. A subset of FOLR2+ macrophages is embedded in plasma cell niches. NLRP3+ macrophages co-localize with neutrophils and activate an inflammasome in tumors. Our findings indicate th
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10The Rationale for Radiation Therapy in Alzheimer's Disease - 4 month(s) ago
Alzheimer’s Disease (AD) represents a major health problem without effective treatments. As the incidence of the disease will continue to rise, it is imperative to find new treatment options to halt or slow disease progression. In recent years, several groups have begun to study the utility of low total dose radiation therapy (LTDRT) to inhibit some of the pathological features of AD and improve cognition in a variety of animal models. These preclinical studies have led to Phase 1 and 2 trials in different centers around the world. In this review, we present and interpret the pre-clinical evidence report some preliminary clinical data from a Phase 2 trial in early-stage AD patients.
Source: bioone.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8The Rationale for Radiation Therapy in Alzheimer's Disease - 4 month(s) ago
Alzheimer’s Disease (AD) represents a major health problem without effective treatments. As the incidence of the disease will continue to rise, it is imperative to find new treatment options to halt or slow disease progression. In recent years, several groups have begun to study the utility of low total dose radiation therapy (LTDRT) to inhibit some of the pathological features of AD and improve cognition in a variety of animal models. These preclinical studies have led to Phase 1 and 2 trials in different centers around the world. In this review, we present and interpret the pre-clinical evidence report some preliminary clinical data from a Phase 2 trial in early-stage AD patients.
Source: bioone.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37
Nature – Discovery of the lymphatic vessels that connect the brain to certain neck lymph nodes might help efforts to combat neurodegeneration.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Compartmentalizing damaged DNA: A double-edged sword - 4 month(s) ago
A recent publication in Nature by Arnould et al.1 describes a novel chromatin compartment, termed “damaged” or “D compartment,” that facilitates the repair of DNA double-strand breaks but also increases the risk of potentially oncogenic translocation formation.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
This prospective, randomized, placebo-controlled, double-blind pilot trial in 40 patients receiving radiation therapy for brain tumors showed that Boswellia serrata significantly reduced cerebral ed…
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations - 5 month(s) ago
Brain metastases represent a common problem in patients with cancer. In the United States alone, there are up to 100,000 patients diagnosed with brain metastases annually. Treatment paradigms of patients with brain metastases have become increasingly complex, and the therapeutic approach 1, 2 is typically rendered by a multidisciplinary team that must consider a myriad of factors including tumor burden, location, phenotype, and genotype, as well as patient signs, symptoms, performance status, and goals
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: A Reason for Optimism While Avoiding Overreaching Interpretations - 5 month(s) ago
Brain metastases represent a common problem in patients with cancer. In the United States alone, there are up to 100,000 patients diagnosed with brain metastases annually. Treatment paradigms of patients with brain metastases have become increasingly complex, and the therapeutic approach 1, 2 is typically rendered by a multidisciplinary team that must consider a myriad of factors including tumor burden, location, phenotype, and genotype, as well as patient signs, symptoms, performance status, and goals
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer - 6 month(s) ago
Abstract. Background: PSMA-based targeted radionuclide therapy is now a standard of care for mCRPC since approval of 177Lu-PSMA-617. Use of antibodies (e.g., J591) to target PSMA with higher potency radionuclides (e.g., 225Ac) impacts kinetics, biodistribution, clinical efficacy, and toxicities. In our first-in-human ph I dose-escalation study of single dose 225Ac-J591 in patients with mCRPC, no MTD was reached (max dose 93.3 KBq/kg). Following this, we developed ph I/II parallel dose-escalation studies of fractionated (D1, D15) single cycle and multiple (q6w) dose regimens. Here we present safety data from the initial fractionated study in predominantly 177Lu-naive.Methods: Eligible patients had adequate organ function, ECOG performance status 0-2, and progressive mCRPC following potent AR pathway inhibitor (ARPI) and chemo (or unfit/refusing). Prior 177Lu-PSMA was allowed until an amendment developed a separate study for post-177Lu-PSMA. Baseline 68Ga-PSMA PET scans were performed, b
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 33IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer - 6 month(s) ago
Nature – Single-cell and spatial gene expression analyses of pancreatic ductal adenocarcinoma uncover a population of interleukin-1β-expressing macrophages that drive inflammatory…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
RT @MagdaMatusiak: Here is the link to Cancer Discovery Online First: https://t.co/tuM936hi36